The device comes with Medtronic's AdaptivCRT algorithms which can improve the patients' response to the therapy and reduce the risk of atrial fibrillation by preserving normal heart rhythms and automatically adjusting to the patient's needs every minute.
The company added that other tools such as OptiVol Fluid Status Monitoring and Cardiac Compass Report also feature in the device, providing an accurate assessment of rehospitalization risk within 30 days of discharge. While Viva CRT-P has been approved it Europe, it is yet to gain approval from the US Food and Drug Administration.
"The diagnostic capabilities of this smart device help improve function throughout the continuum of care. This represents a win for both patients and physicians and, when coupled with additional longevity, provides another layer of distinct value over a longer period", Medtronic's David Steinhaus said.